Form 8-K - Current report:
SEC Accession No. 0001714899-24-000233
Filing Date
2024-11-18
Accepted
2024-11-18 16:02:29
Documents
15
Period of Report
2024-11-12
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20241112.htm   iXBRL 8-K 35075
2 EX-3.1 amendedandrestatedbylawsof.htm EX-3.1 255139
6 image.jpg GRAPHIC 344
  Complete submission text file 0001714899-24-000233.txt   457807

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20241112.xsd EX-101.SCH 1815
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20241112_lab.xml EX-101.LAB 22532
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20241112_pre.xml EX-101.PRE 13065
17 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20241112_htm.xml XML 2830
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 241471420
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)